Filing Flows › China Pharma Holdings (CPHI) › Q2 2025
China Pharma Holdings (CPHI) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
China Pharma Holdings (CPHI) reported revenue of $1.0M for the second quarter 2025 (Q2 2025), +11% from a year earlier and -10% from the quarter before. Operating margin was -63.6%, net loss $528K (51.5% of revenue).
China Pharma Holdings, Q2 2025: revenue $1.0M (+11% year over year), operating margin -63.6%, net loss $528K, operating cash flow $291K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0M | -10% | +11% |
| Operating profit | −$652K | — | — |
| Net earnings | −$528K | — | — |
| Operating cash flow | $291K | — | — |
What changed
Revenue was $1.0M in Q2 2025, up 11% year over year and down 10% from the previous quarter.
Operating costs exceeded revenue by $652K, an operating margin of -63.6%. Total costs fell 28% while revenue rose 11%. The fastest-growing cost line was General & admin (+380%). The quarter ended with a net loss of $528K, narrower than the previous quarter's $786K loss. Non-operating items added $124K, -23% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $291K. Non-cash charges added back $321K of depreciation and amortization. Working capital and other items added $499K. Capital expenditures of −$0K left free cash flow of $291K.
Questions
What was China Pharma Holdings' revenue in the second quarter 2025?
China Pharma Holdings (CPHI) reported revenue of $1.0M for the second quarter 2025 (Q2 2025), +11% from a year earlier and -10% from the quarter before.
Was China Pharma Holdings profitable in the second quarter 2025?
Operating loss was $652K (-63.6% of revenue) and net loss $528K.